US Government Received $400 Million in COVID-19 Vaccine Royalty Payments: Moderna
Moderna said on Feb. 23 that it recently reached a patent agreement with the U.S. government over disputed technology that is featured in its COVID-19 vaccine.
In December 2022, Moderna entered “a nonexclusive patent license agreement” with the National Institute of Allergy and Infectious Diseases (NIAID), said CFO Jamey Mock during an earnings call on Thursday.
The agreement lets the company use “certain patent rights concerning stabilizing prefusion coronavirus spike proteins and the resulting stabilized proteins for the use in COVID-19 vaccine products,” Mock said.
Under the agreement, Moderna sent a “catch-up payment” of $400 million to the NIAID before the new year, according to Moderna executives….